ArticleBMC medicine2016
Successful external validation of a model to predict other cause mortality in localized prostate cancer.
Article in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts.Age and ageing · 2026Observational
- Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer-specific Death in Sweden: A Population-based Cohort Study.European urology open science · 2025Article
- Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.The Journal of urology · 2024Article
- Estimating patient health in prostate cancer treatment counseling.Prostate cancer and prostatic diseases · 2023Article
- Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction.European urology focus · 2023Article
- Development and validation of a life expectancy calculator for US patients with prostate cancer.BJU international · 2022Article
- Article
- Prostate cancer risk group is associated with other-cause mortality in men with localized prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy.World journal of urology · 2019Article
- A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy.Journal of personalized medicine · 2019Article
- Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer.JCO clinical cancer informatics · 2019Article
- Article
- Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic.JCO clinical cancer informatics · 2018Article
- Rethinking active surveillance for prostate cancer in African American men.Translational andrology and urology · 2018Review
- The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.BMC medicine · 2018Article
- A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.Targeted oncology · 2017Article
- On Risk Estimation versus Risk Stratification in Early Prostate Cancer.PLoS medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough life expectancy estimation is vital to decision making for localized prostate cancer, there are few, if any, valid and usable tools. Our goal was to create and validate a prediction model for other cause mortality in localized prostate cancer patients that could aid clinician's initial treatment decisions at the point of care.
methodsWe combined an adjusted Social Security Administration table with a subset of comorbidities from a UK actuarial life expectancy model. Life tables were adjusted on the basis of survival data from a cohort of almost 10,000 radical prostatectomy patients treated at four major US academic institutions. Comorbidity-specific odds ratios were calculated and incorporated with baseline risk of mortality. We externally validated the model on 2898 patients from the Prostate Cancer Outcomes Study, which included men diagnosed with prostate cancer in six SEER cancer registries. These men had sufficient follow-up for our endpoints of 10- and 15-year mortality and also had self-reported comorbidity data.
resultsLife expectancy for prostate cancer patients were close to that of a typical US man who was 3 years younger. On external validation, 10- and 15-year concordance indexes were 0.724 and 0.726, respectively. Our model exhibited excellent calibration. Taking into account differences between how comorbidities are used in the model versus how they were recorded in the validation cohort, calibration would improve for most patients, but there would be overestimation of the risk of death in the oldest and sickest patients.
conclusionsWe successfully created and externally validated a new life expectancy prediction model that, while imperfect, has clear advantages to any alternative. We urge consideration of its use in counseling patients with localized prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.